Trademark Overview
On Monday, February 23, 2026, a trademark application was filed for TARGNYRVA with the United States Patent and Trademark Office. The USPTO has given the TARGNYRVA trademark a serial number of 99665406. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Monday, February 23, 2026. This trademark is owned by Glaxo Group Limited. The TARGNYRVA trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives